Metastatic cancer Patients are treated with targeted therapeutics to which they develop resistance that causes relapse followed by patient death. Utilizing our ResistomeTM platform we can rapidly identify the resistance mechanism and ahead of the competition, develop drugs to combat resistance. We will develop them to Phase I/IIa, followed by out-licensing to pharma. These B2B deals range from $100–300M upfront payments + milestones & royalties.